Background: Hyperbilirubinemia is a common complication of sepsis. Elevated bilirubin may induce inflammation and apoptosis. We hypothesized that increased serum bilirubin on ICU admission contributes to sepsis-related ARDS.
Methods: Serum bilirubin on ICU admission was measured in 1006 septic patients. Serial serum bilirubin was analyzed prospectively in septic patients with ARDS for a period of 28 days. The effects of clinical factors and variants of UGT1A1 gene on serum bilirubin levels were determined. Outcomes were ARDS risk and mortality.
Results: During 60 day follow-up, 326 septic patients developed ARDS in whom 144 died from ARDS. The hyperbilirubinemia (≥ 2.0 mg/dl) rate in patients with ARDS (22.4%) was higher than those without ARDS (14.1%, p = 0.002). For each 1.0 mg/dL increase in admission bilirubin, ARDS risk, 28- and 60-day ARDS mortality were increased by 7% (OR = 1.07; p = 0.003), 20% (OR, 1.20; p = 0.002), and 18% (OR = 1.18; p = 0.004), respectively. Compared with subjects with bilirubin levels < 2.0 mg/dl, patients with hyperbilirubinemia had higher risks of ARDS (OR = 2.12; p = 0.0007), 28-day (OR = 2.24; p = 0.02), and 60-day ARDS mortality (OR = 2.09; p = 0.020). In sepsis-related ARDS, serial bilirubin levels in non-survivors were consistently higher than in survivors (p < 0.0001). Clinical variables explained 29.5% of the inter-individual variation in bilirubin levels, whereas genetic variants of UGT1A1 contributed 7.5%.
Conclusion: In sepsis, higher serum bilirubin level on ICU admission is associated with subsequent ARDS development and mortality.
Statistics from Altmetric.com
Review history and Supplementary material
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.